Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with <i>RAS</i>/<i>BRAF</i> Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial

Huabin Hu, Yanhong Deng, Meijin Huang et al.|The Oncologist|2020

Cited by 50